Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA approves Edwards' porcine replacement heart valve:

This article was originally published in Clinica

Executive Summary

The US FDA has approved Edwards Lifesciences' Carpentier-Edwards SAV porcine replacement heart valve, which the firm says has a 20-year history outside of the US. The bioprosthesis allows for supra-annular implantation - above a patient's native aortic valve, rather than directly into the aortic annulus - and a proprietary scalloped sewing band for optimising anatomic fit. Supra-annular placement allows surgeons to implant a larger-orifice valve, which provides improved haemodynamic performance over intra-annularly placed porcine aortic heart valves, explains the Irvine, California firm. The valve also features Edwards' XenoLogiX tissue treatment.

You may also be interested in...

US FDA Commissioner Hahn’s Star Turn: Baptism By Fire Turns Perilous

Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?

Keeping Track: US FDA Okays BMS’ Zeposia In MS, Nixes Lilly/BI’s Empagliflozin For Type 1 Diabetes

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts